MCID: PNC041
MIFTS: 54

Pancreatic Ductal Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Ductal Adenocarcinoma

MalaCards integrated aliases for Pancreatic Ductal Adenocarcinoma:

Name: Pancreatic Ductal Adenocarcinoma 39 12 15 17 74
Ductal Adenocarcinoma of the Pancreas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3498
NCIt 51 C9120
UMLS 74 C1335302

Summaries for Pancreatic Ductal Adenocarcinoma

Disease Ontology : 12 A pancreatic adenocarcinoma that derives from pancreatic duct cells.

MalaCards based summary : Pancreatic Ductal Adenocarcinoma, also known as ductal adenocarcinoma of the pancreas, is related to cholangiocarcinoma and pancreatic cancer, and has symptoms including abdominal pain, pruritus and icterus. An important gene associated with Pancreatic Ductal Adenocarcinoma is MIR155 (MicroRNA 155), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Paclitaxel and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, pancreas and lymph node.

Related Diseases for Pancreatic Ductal Adenocarcinoma

Diseases related to Pancreatic Ductal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
# Related Disease Score Top Affiliating Genes
1 cholangiocarcinoma 31.1 AFAP1-AS1 DAPK1 H19 MALAT1 MIR21 UCA1
2 pancreatic cancer 31.0 AFAP1-AS1 H19 HOTAIR HOTTIP LINC00673 MALAT1
3 renal cell carcinoma, nonpapillary 30.5 H19 HOTAIR MALAT1 PVT1 UCA1
4 melanoma 30.5 H19 HOTAIR HOTAIRM1 LINC00673 MALAT1 PVT1
5 hepatocellular carcinoma 30.4 AFAP1-AS1 H19 HOTAIR HOTTIP MALAT1 MIR155
6 breast cancer 30.3 H19 HOTAIR HOTTIP LINC00339 MALAT1 MIR155
7 gastric cancer 29.8 AFAP1-AS1 FEZF1-AS1 H19 HOTAIR HOTTIP LINC00673
8 adenocarcinoma 11.6
9 pancreatitis 10.9
10 triple-receptor negative breast cancer 10.5 HOTAIR MALAT1
11 esophagus squamous cell carcinoma 10.5 AFAP1-AS1 HOTAIR
12 ovarian epithelial cancer 10.5 H19 HOTAIR MALAT1
13 autoimmune pancreatitis 10.5
14 hypoxia 10.5
15 polymyositis 10.5 MIR155 MIR21
16 pituitary adenoma 10.5 H19 HOTAIR MALAT1
17 gastric cardia adenocarcinoma 10.5 H19 HOTAIR
18 lymphoma, hodgkin, classic 10.5 MIR155 MIR21 PVT1
19 laryngeal squamous cell carcinoma 10.5 H19 HOTAIR MALAT1 MIR21
20 dermatomyositis 10.5 MIR155 MIR21
21 gastrointestinal system cancer 10.4 H19 HOTAIR MALAT1
22 small cell cancer of the lung 10.4 HOTAIR HOTTIP MALAT1 MIR21
23 esophagus adenocarcinoma 10.4 AFAP1-AS1 MIR21
24 malignant glioma 10.4 HOTAIR HOTTIP PVT1
25 diffuse large b-cell lymphoma 10.4 HOTAIR MIR155 MIR21
26 squamous cell carcinoma, head and neck 10.4 H19 HOTAIR MIR155 MIR21
27 astrocytoma 10.4 H19 HOTAIR LINC00339 MIR21
28 gallbladder cancer 10.4 AFAP1-AS1 H19 HOTAIR MALAT1 UCA1
29 kidney cancer 10.4 H19 HOTAIR MALAT1 MIR21 PVT1
30 oral squamous cell carcinoma 10.4 H19 HOTAIR MALAT1 MIR155 MIR21 UCA1
31 coronary heart disease 1 10.4 H19 HOTTIP MIR155
32 squamous cell carcinoma 10.4 DAPK1 H19 HOTAIR MALAT1 UCA1
33 microvascular complications of diabetes 3 10.4 MALAT1 PVT1
34 lung cancer susceptibility 3 10.4 AFAP1-AS1 H19 HOTAIR MALAT1 MIR31HG
35 myeloma, multiple 10.4 H19 HOTAIR MALAT1 PVT1 UCA1
36 rheumatoid arthritis 10.4 H19 HOTAIR MALAT1 MIR155 UCA1
37 diabetes mellitus 10.4
38 glioblastoma 10.3 H19 HOTAIR HOTAIRM1 MALAT1 MIR21
39 thyroid cancer 10.3 AFAP1-AS1 H19 HOTAIR MALAT1 PVT1 UCA1
40 leukemia, acute myeloid 10.3 HOTAIR HOTAIRM1 MALAT1 MIR155 MIR21 UCA1
41 thyroid cancer, nonmedullary, 1 10.3 H19 HOTAIR HOTTIP MALAT1 MIR155 PVT1
42 tongue squamous cell carcinoma 10.3 AFAP1-AS1 HOTTIP LINC00673 MALAT1 MIR21 UCA1
43 headache associated with sexual activity 10.3
44 patulous eustachian tube 10.3
45 intrahepatic cholangiocarcinoma 10.3
46 osteogenic sarcoma 10.3 H19 HOTAIR HOTTIP MALAT1 PVT1 UCA1
47 bladder urothelial carcinoma 10.3 HOTAIR MALAT1 PVT1
48 nasopharyngeal carcinoma 10.3 AFAP1-AS1 DAPK1 H19 HOTAIR MALAT1 PVT1
49 b-cell lymphomas 10.3 HOTAIR MALAT1 PVT1
50 glioma 10.3 H19 HOTAIR HOTTIP MALAT1 MIR21 PVT1

Graphical network of the top 20 diseases related to Pancreatic Ductal Adenocarcinoma:



Diseases related to Pancreatic Ductal Adenocarcinoma

Symptoms & Phenotypes for Pancreatic Ductal Adenocarcinoma

UMLS symptoms related to Pancreatic Ductal Adenocarcinoma:


abdominal pain, pruritus, icterus

Drugs & Therapeutics for Pancreatic Ductal Adenocarcinoma

Drugs for Pancreatic Ductal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 191)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 33069-62-4 36314
2
Gemcitabine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 95058-81-4 60750
3 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
4 Antimetabolites Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
5 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
6 Immunosuppressive Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
7 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
8 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
9 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
10 Antimitotic Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
11 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
12
Pancrelipase Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 53608-75-6
13
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
14
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
15
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
16
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 143 6006
17
Hyaluronic acid Approved, Vet_approved Phase 3,Phase 2 9004-61-9 53477741
18
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
20
Calcium Approved, Nutraceutical Phase 3,Phase 2,Phase 1 7440-70-2 271
21 Protective Agents Phase 3,Phase 2,Phase 1,Not Applicable
22 acivicin Phase 3,Phase 2
23 pancreatin Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
24 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
25 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
26 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
27 Folate Phase 3,Phase 2,Phase 1
28 Vitamin B9 Phase 3,Phase 2,Phase 1
29 Micronutrients Phase 3,Phase 2,Phase 1
30 Vitamins Phase 3,Phase 2,Phase 1
31 Trace Elements Phase 3,Phase 2,Phase 1
32 Nutrients Phase 3,Phase 2,Phase 1
33 Vitamin B Complex Phase 3,Phase 2,Phase 1
34 Antidotes Phase 3,Phase 2,Phase 1
35
Erlotinib Hydrochloride Phase 3,Phase 1,Phase 2 183319-69-9 176871
36 Calcium, Dietary Phase 3,Phase 2,Phase 1
37 Adjuvants, Immunologic Phase 3,Phase 1
38 Viscosupplements Phase 3
39 Hematinics Phase 3,Phase 1
40
asparaginase Phase 3
41 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide Phase 3,Phase 1
42
Cisplatin Approved Phase 1, Phase 2,Phase 2 15663-27-1 2767 441203 84093
43
Olaparib Approved Phase 2 763113-22-0 23725625
44
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
45
Durvalumab Approved, Investigational Phase 2,Phase 1 1428935-60-7
46
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
47
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
48
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
49
Enoxaparin Approved Phase 2 9005-49-6 772
50
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743

Interventional clinical trials:

(show top 50) (show all 188)
# Name Status NCT ID Phase Drugs
1 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Recruiting NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
2 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Withdrawn NCT02570529 Phase 4 Albis®;Placebo
3 A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Active, not recruiting NCT02715804 Phase 3 Placebo;Nab-paclitaxel;Gemcitabine
4 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
5 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Active, not recruiting NCT01013649 Phase 3 Capecitabine;Chemotherapy;Erlotinib Hydrochloride;Fluorouracil;Gemcitabine Hydrochloride
6 Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma Not yet recruiting NCT03943667 Phase 3 Gemcitabine;Paclitaxel
7 Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer Not yet recruiting NCT03317886 Phase 3
8 Evaluation of Complete microscopicE Resection Margin (R0) and Lymph Node Involvement After Standard Pancreatosplenectomy (SPS) Versus Radical Anterograde Modular Pancreatosplenectomy Not yet recruiting NCT03679169 Phase 3
9 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PDAC Not yet recruiting NCT03665441 Phase 3 eryaspase;Gemcitabine plus Abraxane;Irinotecan plus 5-FU plus leucovorin
10 Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Terminated NCT02101021 Phase 3 Momelotinib;Placebo to match momelotinib;Nab-paclitaxel;Gemcitabine
11 Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA) Unknown status NCT01893801 Phase 1, Phase 2 nab-paclitaxel;Cisplatin;gemcitabine
12 Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma Unknown status NCT01021800 Phase 2
13 Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer Unknown status NCT02124317 Phase 2 nanoparticle albumin-bound paclitaxel;S-1
14 Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer Unknown status NCT02135822 Phase 2 nanoparticle albumin-bound paclitaxel;gemcitabine
15 Efficacy and Safety of PARPi to Treat Pancreatic Cancer Unknown status NCT02511223 Phase 2 OLAPARIB
16 Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Completed NCT02558894 Phase 2 MEDI4736 monotherapy;tremelimumab+MEDI4736
17 Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Completed NCT02583477 Phase 1, Phase 2 MEDI4736 in combination with nab-paclitaxel and gemcitabine;MEDI4736 in combination with AZD5069
18 Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02289898 Phase 2 Demcizumab;Abraxane®;gemcitabine;Placebo
19 Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial Completed NCT02440958 Phase 2 modified FOLFIRINOX regimen
20 Scheduling Nab-paclitaxel With Gemcitabine Completed NCT03529175 Phase 2 Abraxane (nab-paclitaxel);Gemcitabine
21 Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer Completed NCT01580397 Phase 2 INNO-206
22 A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation Completed NCT02042378 Phase 2 Rucaparib
23 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Completed NCT00585078 Phase 2 Capecitabine;Oxaliplatin
24 PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Completed NCT01839487 Phase 2 PEGPH20;Nab-paclitaxel;Gemcitabine;Dexamethasone;Enoxaparin
25 Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy Completed NCT01658943 Phase 2 Akt Inhibitor MK2206;Fluorouracil;Oxaliplatin;Selumetinib
26 Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Completed NCT01280058 Phase 2 Carboplatin;Paclitaxel
27 Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma Recruiting NCT03727880 Phase 2 Pembrolizumab;Defactinib
28 BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting NCT03496662 Phase 1, Phase 2 BMS-813160;Nivolumab;Gemcitabine;Nab-paclitaxel
29 Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02426281 Phase 2 nab-paclitaxel;gemcitabine
30 Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02754726 Phase 2 Nivolumab;Albumin-bound paclitaxel;Paricalcitol;Cisplatin;Gemcitabine
31 Maintenance Therapy With OSE2101 Vaccine Alone or in Combination With Nivolumab, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT03806309 Phase 2 FOLFIRI;OSE2101;Nivolumab
32 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Recruiting NCT03193190 Phase 1, Phase 2 Nab-Paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Fluorouracil;Atezolizumab;Cobimetinib;PEGPH20;BL-8040;Selicrelumab;Bevacizumab;Emactuzumab;RO6874281
33 PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma Recruiting NCT02487277 Phase 2 PEGPH20;Gemcitabine;Nab-paclitaxel
34 Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC Recruiting NCT03634332 Phase 2 PEGPH20
35 A Phase II Study of Neoadjuvant FOLFIRINOX Recruiting NCT02178709 Phase 2 FOLFIRINOX
36 Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma Recruiting NCT03610490 Phase 2 Cyclophosphamide;Fludarabine
37 Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) Recruiting NCT03415854 Phase 2 Paricalcitol (Zemplar)
38 Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions Recruiting NCT03486327 Phase 2 BR55
39 Study of NAC of GA Therapy for Patients With BRPC Recruiting NCT02926183 Phase 2 Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel
40 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates Recruiting NCT02723331 Phase 2 Nab-paclitaxel and gemcitabine for R-PDAC Patients;Nab-paclitaxel and gemcitabine for BR-PDAC Patients
41 A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy Recruiting NCT03331640 Phase 2 OFF;FOLFIRI Protocol
42 A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer Recruiting NCT01676259 Phase 2 siG12D-LODER;Gemcitabine+nab-Paclitaxel
43 Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma Recruiting NCT03469258 Phase 2 Pancrelipase
44 MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study Recruiting NCT03611556 Phase 1, Phase 2 gemcitabine;nab-paclitaxel
45 Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Recruiting NCT02125136 Phase 2 Gem/nab-Pac;FOLFIFINOX
46 Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. Recruiting NCT03525392 Phase 1, Phase 2 177Lu-3BP-227 (also called 177Lu-IPN01087)
47 Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer Recruiting NCT03636308 Phase 2 nanoparticle albumin-bound paclitaxel;S1;Gemcitabine
48 Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer Recruiting NCT02047513 Phase 2 perioperative nab-paclitaxel/gemcitabine;adjuvant nab-paclitaxel/gemcitabine
49 Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer Recruiting NCT02806687 Phase 2 Gene Therapy product CYL-02;Gemcitabine
50 Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma Recruiting NCT02743975 Phase 1, Phase 2 Bevacizumab-800CW

Search NIH Clinical Center for Pancreatic Ductal Adenocarcinoma

Genetic Tests for Pancreatic Ductal Adenocarcinoma

Anatomical Context for Pancreatic Ductal Adenocarcinoma

MalaCards organs/tissues related to Pancreatic Ductal Adenocarcinoma:

42
Pancreas, Lymph Node, T Cells, Neutrophil, Testes, Prostate, Bone
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Ductal Adenocarcinoma:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Ducts Affected by disease

Publications for Pancreatic Ductal Adenocarcinoma

Articles related to Pancreatic Ductal Adenocarcinoma:

(show top 50) (show all 2286)
# Title Authors Year
1
Pancreatic Ductal Adenocarcinoma Development in the Remnant Pancreas after Pancreaticoduodenectomy for Acinar Cell Carcinoma: A Case Report. ( 31061255 )
2019
2
Sonic Hedgehog Ligand: A Role in Formation of a Mesenchymal Niche in Human Pancreatic Ductal Adenocarcinoma. ( 31072042 )
2019
3
MRI Assessment of Associations between Brown Adipose Tissue and Cachexia in Murine Pancreatic Ductal Adenocarcinoma. ( 31073508 )
2019
4
Vasohibin-2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma. ( 31074083 )
2019
5
Magnesium transporter protein solute carrier family 41 member 1 suppresses human pancreatic ductal adenocarcinoma through magnesium-dependent Akt/mTOR inhibition and bax-associated mitochondrial apoptosis. ( 31076559 )
2019
6
MicroRNA profiling of pancreatic ductal adenocarcinoma (PDAC) reveals signature expression related to lymph node metastasis. ( 31080555 )
2019
7
Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. ( 31082915 )
2019
8
High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma. ( 31088413 )
2019
9
Insulin-like growth factor 2 mRNA binding protein 2 promotes aerobic glycolysis and cell proliferation in pancreatic ductal adenocarcinoma via stabilizing GLUT1 mRNA. ( 31089713 )
2019
10
Response to: Comment on "The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma." By Niccolo Petrucciani, MD, PhD, FACS, Laura Antolino, MD, Giovanni Moschetta, MD, Giovanni Ramacciato, MD, FACS. ( 31090562 )
2019
11
Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma. ( 31091213 )
2019
12
Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of the gland. ( 31093997 )
2019
13
Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice. ( 31100067 )
2019
14
Vitamin C and Vitamin E Mitigate the Risk of Pancreatic Ductal Adenocarcinoma from Meat-Derived Mutagen Exposure in Adults in a Case-Control Study. ( 31100111 )
2019
15
Consumption of nuts and seeds and pancreatic ductal adenocarcinoma risk in the European Prospective Investigation into cancer and Nutrition. ( 31107546 )
2019
16
Differential effects of depleting versus programming tumor-associated macrophages on engineered T cells in pancreatic ductal adenocarcinoma. ( 31028033 )
2019
17
Differentiating focal autoimmune pancreatitis and pancreatic ductal adenocarcinoma: contrast-enhanced MRI with special emphasis on the arterial phase. ( 31028441 )
2019
18
Lessons learned by features of pancreatic ductal adenocarcinoma and its tumor microenvironment. ( 31032290 )
2019
19
Incidence and Significance of GATA3 Positivity in Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma. ( 31033498 )
2019
20
IDENTIFICATION OF MRP4/ABCC4 AS A TARGET FOR REDUCING THE PROLIFERATION OF PANCREATIC DUCTAL ADENOCARCINOMA CELLS BY MODULATING THE cAMP EFFLUX. ( 31043460 )
2019
21
Prognostic significance of EIF4G1 in patients with pancreatic ductal adenocarcinoma. ( 31043796 )
2019
22
Oncogenic ERBB2 Aberrations and KRAS Mutations Cooperate to Promote Pancreatic Ductal Adenocarcinoma Progression. ( 31046123 )
2019
23
BRM270 Inhibits the Proliferation of CD44 Positive Pancreatic Ductal Adenocarcinoma Cells via Downregulation of Sonic Hedgehog Signaling. ( 31049070 )
2019
24
Cystatin F as a key family 2 cystatin subunit and prognostic biomarker for early‑stage pancreatic ductal adenocarcinoma. ( 31059105 )
2019
25
Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma. ( 31059520 )
2019
26
Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions. ( 31060750 )
2019
27
Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection. ( 31064193 )
2019
28
A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. ( 31065624 )
2019
29
Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma. ( 31066938 )
2019
30
NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma. ( 31068372 )
2019
31
Association between hyperechogenic pancreas and pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasms. ( 31069577 )
2019
32
Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy. ( 31070038 )
2019
33
Inflammation and development of pancreatic ductal adenocarcinoma. ( 31070039 )
2019
34
Meta-Analysis of 1,200 Transcriptomic Profiles Identifies a Prognostic Model for Pancreatic Ductal Adenocarcinoma. ( 31070984 )
2019
35
Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Ductal Adenocarcinoma Patients. ( 30974894 )
2019
36
Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma. ( 30976063 )
2019
37
Overexpression and Tyr421-phosphorylation of cortactin is induced by three-dimensional spheroid culturing and contributes to migration and invasion of pancreatic ductal adenocarcinoma (PDAC) cells. ( 30976201 )
2019
38
Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma. ( 30980401 )
2019
39
Prognostic value of adjacent organ resection in patients with left-sided pancreatic ductal adenocarcinoma following distal pancreatectomy. ( 30980486 )
2019
40
Protein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma. ( 30982078 )
2019
41
Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX. ( 30993652 )
2019
42
Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis. ( 30993653 )
2019
43
Prognostic Relevance of Tertiary Lymphoid Organs Following Neoadjuvant Chemoradiotherapy in Pancreatic Ductal Adenocarcinoma. ( 30997706 )
2019
44
BAG3 Suppresses Loading of Ago2 to IL6 mRNA in Pancreatic Ductal Adenocarcinoma. ( 31001483 )
2019
45
Utility of CT Radiomics Features in Differentiation of Pancreatic Ductal Adenocarcinoma From Normal Pancreatic Tissue. ( 31012758 )
2019
46
Preclinical evaluation of 68Ga-DOTA-NT-20.3: A promising PET imaging probe to discriminate human pancreatic ductal adenocarcinoma from pancreatitis. ( 31013092 )
2019
47
Tumor location as an indicator of survival in T1 resectable pancreatic ductal adenocarcinoma: a propensity score-matched analysis. ( 31014264 )
2019
48
Differentiation between non-hypervascular pancreatic neuroendocrine tumour and pancreatic ductal adenocarcinoma on dynamic computed tomography and non-enhanced magnetic resonance imaging. ( 31019610 )
2019
49
Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level meta-analysis and proposition of the Beaujon score. ( 31019704 )
2019
50
The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells. ( 31025257 )
2019

Variations for Pancreatic Ductal Adenocarcinoma

Copy number variations for Pancreatic Ductal Adenocarcinoma from CNVD:

7 (show top 50) (show all 315)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14616 1 109662726 110421733 Loss Pancreatic ductal adenocarcinoma
2 14979 1 111694621 112653686 Loss Pancreatic ductal adenocarcinoma
3 15141 1 11296895 11700048 Loss Pancreatic ductal adenocarcinoma
4 15254 1 113902673 114772618 Loss Pancreatic ductal adenocarcinoma
5 21071 1 156591077 157602759 Gain Pancreatic ductal adenocarcinoma
6 22927 1 16990962 17780550 Loss Pancreatic ductal adenocarcinoma
7 23665 1 172632928 173462394 Gain Pancreatic ductal adenocarcinoma
8 23983 1 174098656 174792564 Gain Pancreatic ductal adenocarcinoma
9 24268 1 17780550 18767187 Loss Pancreatic ductal adenocarcinoma
10 25340 1 18767187 19870518 Loss Pancreatic ductal adenocarcinoma
11 25429 1 189012940 189640525 Gain Pancreatic ductal adenocarcinoma
12 25525 1 190940606 191897513 Gain Pancreatic ductal adenocarcinoma
13 25603 1 191897513 192833019 Gain Pancreatic ductal adenocarcinoma
14 25668 1 192833019 193928417 Gain Pancreatic ductal adenocarcinoma
15 25957 1 195125528 196179631 Gain Pancreatic ductal adenocarcinoma
16 26123 1 197274194 198251428 Gain Pancreatic ductal adenocarcinoma
17 26286 1 19870518 21264484 Loss Pancreatic ductal adenocarcinoma
18 27649 1 210637543 211466127 Gain Pancreatic ductal adenocarcinoma
19 29512 1 232834654 234059648 Gain Pancreatic ductal adenocarcinoma
20 29988 1 23881482 24596143 Loss Pancreatic ductal adenocarcinoma
21 30783 1 24596143 24901021 Loss Pancreatic ductal adenocarcinoma
22 31049 1 24901021 26202341 Loss Pancreatic ductal adenocarcinoma
23 31229 1 26202341 27453508 Loss Pancreatic ductal adenocarcinoma
24 31475 1 27702974 28279739 Loss Pancreatic ductal adenocarcinoma
25 31649 1 29154418 29949616 Loss Pancreatic ductal adenocarcinoma
26 31710 1 29949616 31202941 Loss Pancreatic ductal adenocarcinoma
27 31822 1 31202941 32179980 Loss Pancreatic ductal adenocarcinoma
28 32104 1 33581730 34569385 Loss Pancreatic ductal adenocarcinoma
29 32211 1 34569385 35804738 Loss Pancreatic ductal adenocarcinoma
30 32498 1 36953732 37599763 Loss Pancreatic ductal adenocarcinoma
31 32649 1 38143717 38830556 Loss Pancreatic ductal adenocarcinoma
32 32759 1 3913633 5229374 Loss Pancreatic ductal adenocarcinoma
33 33297 1 44268667 45000776 Loss Pancreatic ductal adenocarcinoma
34 33745 1 47532872 48556325 Loss Pancreatic ductal adenocarcinoma
35 34094 1 5229374 6509870 Loss Pancreatic ductal adenocarcinoma
36 34199 1 53371440 53750907 Loss Pancreatic ductal adenocarcinoma
37 34230 1 53750907 54788971 Loss Pancreatic ductal adenocarcinoma
38 36948 1 8379388 9142502 Loss Pancreatic ductal adenocarcinoma
39 37455 1 9142502 9661749 Loss Pancreatic ductal adenocarcinoma
40 38508 10 103075332 103271952 Gain Pancreatic ductal adenocarcinoma
41 41307 10 15917593 17007248 Gain Pancreatic ductal adenocarcinoma
42 41728 10 22854210 23744923 Gain Pancreatic ductal adenocarcinoma
43 44446 10 57203760 58367659 Gain Pancreatic ductal adenocarcinoma
44 44911 10 64846281 66342495 Gain Pancreatic ductal adenocarcinoma
45 45553 10 72143312 73316160 Loss Pancreatic ductal adenocarcinoma
46 45655 10 73316160 74391172 Gain Pancreatic ductal adenocarcinoma
47 45775 10 74391172 75333936 Gain Pancreatic ductal adenocarcinoma
48 45937 10 75333936 76299818 Gain Pancreatic ductal adenocarcinoma
49 46231 10 79273961 80171344 Loss Pancreatic ductal adenocarcinoma
50 46288 10 80171344 81279277 Loss Pancreatic ductal adenocarcinoma

Expression for Pancreatic Ductal Adenocarcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Pancreatic Ductal Adenocarcinoma patients vs. healthy controls: 35 (show top 50) (show all 375)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 SYCN syncollin Pancreas - 8.04 0.000
2 GP2 glycoprotein 2 (zymogen granule membrane) Pancreas - 7.99 0.000
3 ALB albumin Pancreas - 7.95 0.000
4 SERPINI2 serpin peptidase inhibitor, clade I (pancpin), member 2 Pancreas - 7.95 0.000
5 CELA2B chymotrypsin-like elastase family, member 2B Pancreas - 7.74 0.000
6 PNLIPRP1 pancreatic lipase-related protein 1 Pancreas - 7.66 0.000
7 PDIA2 protein disulfide isomerase family A, member 2 Pancreas - 7.53 0.000
8 SPX spexin hormone Pancreas - 7.53 0.000
9 CTRL chymotrypsin-like Pancreas - 7.52 0.000
10 COL10A1 collagen, type X, alpha 1 Pancreas + 7.52 0.000
11 CELP carboxyl ester lipase pseudogene Pancreas - 7.50 0.000
12 COL5A1 collagen, type V, alpha 1 Pancreas + 7.46 0.000
13 SULF1 sulfatase 1 Pancreas + 7.38 0.000
14 CUZD1 CUB and zona pellucida-like domains 1 Pancreas - 7.29 0.000
15 POSTN periostin, osteoblast specific factor Pancreas + 7.24 0.000
16 COL1A1 collagen, type I, alpha 1 Pancreas + 7.17 0.000
17 AQP8 aquaporin 8 Pancreas - 7.14 0.000
18 CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 Pancreas + 7.10 0.000
19 COL11A1 collagen, type XI, alpha 1 Pancreas + 7.00 0.000
20 CLPS colipase, pancreatic Pancreas - 6.99 0.000
21 INHBA inhibin, beta A Pancreas + 6.95 0.000
22 CPA2 carboxypeptidase A2 (pancreatic) Pancreas - 6.88 0.000
23 CTRC chymotrypsin C (caldecrin) Pancreas - 6.87 0.000
24 CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) Pancreas + 6.86 0.000
25 PLA2G1B phospholipase A2, group IB (pancreas) Pancreas - 6.79 0.001
26 COL3A1 collagen, type III, alpha 1 Pancreas + 6.78 0.000
27 SFRP4 secreted frizzled-related protein 4 Pancreas + 6.76 0.000
28 CELA3A chymotrypsin-like elastase family, member 3A Pancreas - 6.76 0.001
29 GNMT glycine N-methyltransferase Pancreas - 6.74 0.000
30 COL1A2 collagen, type I, alpha 2 Pancreas + 6.72 0.000
31 REG1P regenerating islet-derived 1 pseudogene Pancreas - 6.72 0.000
32 S100P S100 calcium binding protein P Pancreas + 6.67 0.000
33 CELA3B chymotrypsin-like elastase family, member 3B Pancreas - 6.66 0.001
34 CEL carboxyl ester lipase Pancreas - 6.63 0.001
35 CTHRC1 collagen triple helix repeat containing 1 Pancreas + 6.60 0.000
36 CPA1 carboxypeptidase A1 (pancreatic) Pancreas - 6.56 0.001
37 VCAN versican Pancreas + 6.51 0.000
38 TMEM52 transmembrane protein 52 Pancreas - 6.40 0.000
39 REG1B regenerating islet-derived 1 beta Pancreas - 6.35 0.002
40 CTSE cathepsin E Pancreas + 6.30 0.000
41 GLS2 glutaminase 2 (liver, mitochondrial) Pancreas - 6.28 0.000
42 KLK1 kallikrein 1 Pancreas - 6.26 0.000
43 GJB2 gap junction protein, beta 2, 26kDa Pancreas + 6.24 0.000
44 REG3G regenerating islet-derived 3 gamma Pancreas - 6.17 0.000
45 PLAU plasminogen activator, urokinase Pancreas + 6.15 0.000
46 COL5A2 collagen, type V, alpha 2 Pancreas + 6.13 0.000
47 SLC39A5 solute carrier family 39 (zinc transporter), member 5 Pancreas - 6.09 0.000
48 ERP27 endoplasmic reticulum protein 27 Pancreas - 6.07 0.000
49 SEMA3C sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C Pancreas + 6.00 0.000
50 PNLIP pancreatic lipase Pancreas - 5.94 0.004
Search GEO for disease gene expression data for Pancreatic Ductal Adenocarcinoma.

Pathways for Pancreatic Ductal Adenocarcinoma

Pathways related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 HOTAIR UCA1

GO Terms for Pancreatic Ductal Adenocarcinoma

Biological processes related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of activated T cell proliferation GO:0042104 9.16 MIR155 MIR21
2 positive regulation of cardiac muscle hypertrophy GO:0010613 8.96 MIR155 MIR21
3 negative regulation of regulatory T cell differentiation GO:0045590 8.62 MIR155 MIR21

Sources for Pancreatic Ductal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....